US20090148488A1 - Bioactive coating for medical devices - Google Patents

Bioactive coating for medical devices Download PDF

Info

Publication number
US20090148488A1
US20090148488A1 US12/390,360 US39036009A US2009148488A1 US 20090148488 A1 US20090148488 A1 US 20090148488A1 US 39036009 A US39036009 A US 39036009A US 2009148488 A1 US2009148488 A1 US 2009148488A1
Authority
US
United States
Prior art keywords
groups
medical implant
keratin
organosilane
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/390,360
Inventor
Mark Van Dyke
Arlene J. Siller-Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keraplast Technologies Ltd
Original Assignee
Keraplast Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keraplast Technologies Ltd filed Critical Keraplast Technologies Ltd
Priority to US12/390,360 priority Critical patent/US20090148488A1/en
Publication of US20090148488A1 publication Critical patent/US20090148488A1/en
Assigned to KMS VENUTRES, INC. reassignment KMS VENUTRES, INC. SECURITY AGREEMENT Assignors: KERAPLAST TECHNOLOGIES, LLC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B60VEHICLES IN GENERAL
    • B60QARRANGEMENT OF SIGNALLING OR LIGHTING DEVICES, THE MOUNTING OR SUPPORTING THEREOF OR CIRCUITS THEREFOR, FOR VEHICLES IN GENERAL
    • B60Q1/00Arrangement of optical signalling or lighting devices, the mounting or supporting thereof or circuits therefor
    • B60Q1/26Arrangement of optical signalling or lighting devices, the mounting or supporting thereof or circuits therefor the devices being primarily intended to indicate the vehicle, or parts thereof, or to give signals, to other traffic
    • B60Q1/2661Arrangement of optical signalling or lighting devices, the mounting or supporting thereof or circuits therefor the devices being primarily intended to indicate the vehicle, or parts thereof, or to give signals, to other traffic mounted on parts having other functions
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D189/00Coating compositions based on proteins; Coating compositions based on derivatives thereof
    • C09D189/04Products derived from waste materials, e.g. horn, hoof or hair
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D189/00Coating compositions based on proteins; Coating compositions based on derivatives thereof
    • C09D189/04Products derived from waste materials, e.g. horn, hoof or hair
    • C09D189/06Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B60VEHICLES IN GENERAL
    • B60RVEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R19/00Wheel guards; Radiator guards, e.g. grilles; Obstruction removers; Fittings damping bouncing force in collisions
    • B60R19/02Bumpers, i.e. impact receiving or absorbing members for protecting vehicles or fending off blows from other vehicles or objects
    • B60R19/48Bumpers, i.e. impact receiving or absorbing members for protecting vehicles or fending off blows from other vehicles or objects combined with, or convertible into, other devices or objects, e.g. bumpers combined with road brushes, bumpers convertible into beds
    • B60R19/50Bumpers, i.e. impact receiving or absorbing members for protecting vehicles or fending off blows from other vehicles or objects combined with, or convertible into, other devices or objects, e.g. bumpers combined with road brushes, bumpers convertible into beds with lights or registration plates
    • B60R2019/505Bumpers, i.e. impact receiving or absorbing members for protecting vehicles or fending off blows from other vehicles or objects combined with, or convertible into, other devices or objects, e.g. bumpers combined with road brushes, bumpers convertible into beds with lights or registration plates with lights

Definitions

  • the present application relates to coatings for medical devices, preferably coatings for medical implants. More particularly, the application relates to bioactive coatings, preferably bioactive coatings comprising keratin having osteoinductive properties.
  • the present application provides a medical implant comprising a passivating coating comprising keratin.
  • the passivating coating comprising a bonding region and a bioactive region.
  • the said bonding region comprises at least one organosilane compound comprising a silane component bound to a surface of said substrate.
  • the bioactive region comprises an organic component of said organosilane bound to a reactive pendant group on the keratin.
  • the present application provides substrates comprising a passivating coating comprising keratin.
  • the passivating coating comprises osteoinductive properties.
  • the passivating coating comprises both osteoinductive properties and osteoconductive properties.
  • the substrate preferably resides on a medical device, most preferably a medical implant.
  • the medical device preferably is selected from the group consisting of tissue engineering constructs, orthopedic implants, dental implants, and ventricular assist devices.
  • the substrate comprises a biocompatible material.
  • the biocompatible material preferably is selected from the group consisting of silicon, metals, metal alloys, and ceramics.
  • a preferred metal comprises titanium, and may be titanium metal or an alloy thereof.
  • a preferred ceramic comprises hydroxyapatite.
  • the passivating coating comprises keratin and, in a preferred embodiment, one or more bioactive factors selected from the group consisting of bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-.beta.).
  • BMP bone morphogenetic protein
  • TGF-.beta transforming growth factor beta
  • the keratin is derived from a material selected from the group consisting of hair, fir, feathers, horns, hooves, beaks, or feet.
  • the keratin preferably is derived from hair, more preferably from human hair, which may be referred to as “human hair keratin.”
  • the keratin also preferably comprises reduced keratin.
  • the passivating coating preferably comprises a bonding region and a bioactive region.
  • the bonding region comprises a material adapted to bond with both a surface of the implant and with reactive pendant groups on the keratin.
  • the bonding region comprises at least one silane compound, more preferably an organosilane.
  • the organosilane preferably comprises a silane component and an organic component.
  • the bonding region comprises the silane component bonded with a surface of the medical device and the bioactive region comprises the keratin bonded to the organic component of the organosilane.
  • Suitable organic components for the organosilane are adapted to react with reactive pendant groups on the keratin.
  • the organosilanes preferably comprise an organic component comprising a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups.
  • Preferred organic components comprise a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, and amine groups.
  • More preferred organic components are selected from the group consisting of epoxy groups, acrylate groups, alkoxy groups, vinyl groups, and alkylamine groups. Most preferred organic moieties are selected from the group consisting of vinyl groups and epoxy groups.
  • the organosilane preferably comprises substituents selected from the group consisting of from about 1 to 3 halogens and from about 1 to 3 alkoxy groups. A preferred halogen is chlorine.
  • Also provided is a method of coating a substrate with a passivating substrate comprises: bonding a coupling material to said substrate, producing a bonding region; and, bonding keratin to said bonding region.
  • the method further preferably comprises oxidizing a surface of said substrate before bonding a coupling material to the substrate.
  • the substrate is cleaned before bonding the coupling material to the substrate.
  • the cleaning comprises sonication in anhydrous solvent and sonication in water.
  • Suitable anhydrous solvents include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran.
  • a preferred anhydrous solvent is dichloromethane.
  • the water preferably is deionized water.
  • Bonding keratin to said bonding region comprises dissolving keratin in an appropriate solvent and adding an anhydrous solvent to produce a keratin mixture, exposing said bonding region to said keratin mixture; and curing under conditions effective to produce said bioactive region.
  • an appropriate solvent is water.
  • an appropriate solvent comprises an aqueous solution comprising a base.
  • bases include, but are not necessarily limited to ammonium hydroxide, sodium hydroxide, and/or potassium hydroxide.
  • a preferred base is ammonium hydroxide.
  • Suitable anhydrous solvents include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran.
  • a preferred anhydrous solvent is dimethylsulfoxide.
  • the method further comprises mixing the keratin mixture with a reagent selected from the group consisting of a catalyst and an initiator.
  • a reagent selected from the group consisting of a catalyst and an initiator.
  • a suitable initiator or catalyst generates free radicals.
  • a preferred free radical initiator is selected from the group consisting of anthraquinone-2-sulfonic acid or anthraquinone-2-sulfonic acid sodium salt monohydrate (Aldrich; Milwaukee, Wis.).
  • FIG. 1 is a graph showing the water contact angle of keratin-coated titanium disks, which demonstrates that disks subjected to the process of the present application, silane coating followed by grafting of keratins, had the lowest resulting contact angle.
  • FIG. 2 is a graph showing the water contact angle of keratin-coated substrates demonstrating that both titanium and glass were effectively coated using the dipping process.
  • FIG. 3 is a chart comparing XPS spectra between an untreated titanium disk and a) a silane-coated disk (Si2p spectra) and b) a disk treated with silane, catalyst and keratin (N1s spectra).
  • FIG. 4 is a graph showing Si and N XPS atomic concentrations of keratin-coated titanium disks.
  • FIG. 5 is the estimated thickness of coatings on titanium disks, where the numbers in parenthesis indicate the thickness of the films on the silane coating.
  • FIG. 6 is a micrograph showing that 2T3 cells adhere to and differentiate on keratin-coated titanium disks.
  • the present application selectively extracts keratins from human hair fibers and uses the keratins in a dipping process which produces a molecular coating on the surfaces of medical device materials, such as metals and ceramics.
  • the method uses a coupling agent adapted to bond with both a surface of the implant and with reactive pendant groups on the keratin.
  • the bonding region comprises at least one silane compound, more preferably an organosilane.
  • the organosilane preferably comprises a silane component and an organic component, wherein the bonding region comprises the silane component bonded with a surface of the medical device and the organic component bonded with reactive moieties on the keratin.
  • the silane component of the organosilane is covalently bonded with the surface of the medial device and the organic component of the organosilane is covalently bonded with reactive moieties on the keratin.
  • the coating method is generally applicable to medical device materials, which typically comprise metal and ceramic surfaces.
  • the coating method has the potential of producing a more biocompatible interface and ultimately, biologically active surfaces that promote host acceptance and/or accelerate tissue on growth.
  • Human hair is composed of a tough, tubular outer layer made up of flattened cells arranged in a scaly, overlapping profile known as the cuticle.
  • the inner bulk of the hair is known as the cortex and is constructed from elongated cells that are densely packed with fibrous keratins.
  • the fibrous keratins are arranged in bundles, referred to as macrofibrils, that contain microfibrillar coiled-coils of a-helical keratins.
  • the intermediate filaments (IFs) of this structure are bound together with an to amorphous keratin matrix material.
  • the matrix and IFs vary in function and composition.
  • the matrix is the “glue” that holds the IFs together.
  • This glue is high in sulfur content and is made up of low molecular weight keratins (LMWKs), typically less than 10-15 kDa.
  • LMWKs low molecular weight keratins
  • the IFs are composed of keratins of relatively low sulfur content but high molecular weight (high molecular weight keratins or HMWKs), generally 50-85 kDa.
  • keratins are afforded their structural integrity in large part by the presence of disulfide crosslinks which form a three dimensional network of polypeptide chains. This network structure renders keratins insoluble. Keratins can, however, be made soluble by destroying this three-dimensional structure via diSulfide bond scission. Disulfide bond scission can be done oxidatively, reductively, or by a combination of the two.
  • Disulfide bond scission and selective extraction under controlled conditions results in the isolation of LMWKs from HMWKs.
  • This process serves to remove the cortical proteins without disrupting the cuticle.
  • the inner structure of the hair fiber is removed without substantial damage to the cuticle.
  • the HMWKs from this extraction process give rise to two broad protein bands by gel electrophoresis at molecular weight of 66 kDa and 43 kDa. These keratins are useful as structural biomaterials, including coatings for ceramic and metal surfaces.
  • Growth factors such as bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-.beta.3), are present in the hair follicle, and provide the coatings with osteoinductive and osteoconductive properties.
  • BMP bone morphogenetic protein
  • TGF-.beta.3 transforming growth factor beta
  • Keratin comprises amino acids, which generally have the formula: I
  • Table 1 summarizes the amino acid residues found in human hair, for example, and shows the “R1” groups associated with each residue.
  • cysteine which is found in the form of disulfide-bridged cystine groups. As discussed above, this group can be converted to other sulfur containing moieties, most notably thiol.
  • Thiols theoretically can be reacted with reactive ends of the coupling material using a number of chemical techniques, such as those described in S. Patai (Ed.), the Chemistry of the Thiol Group, Parts 1 and 2, John Wiley & Sons, New York, N.Y. (1974), incorporated herein by reference.
  • Other reaction scenarios such as those directed toward polymer synthesis, also are useful to utilize thiols to form an assortment of desirable crosslinks, including those described in Rempp, P. and Merrill, E.
  • cysteine In addition to cysteine, the following amino acids have pendant groups comprising nitrogen or oxygen which may be useful as reactive pendant groups; arginine, serine, glutamic acid, threonine, aspartic acid, lysine, asparagine, glutamine, tyrosine, tryptophan, and histidine.
  • preferred amino acid residues comprising reactive pendant groups for crosslinking are cysteine, arginine, serine, and glutamic acid, most preferably cysteine and arginine.
  • the keratins may be processed and/or isolated in a number of ways. Preferably, the processing is sufficient to render the resulting proteins water soluble. Suitable processing techniques include known oxidation techniques, reductive techniques, and/or combinations thereof, as long as the processing renders the proteins water soluble without significant hydrolysis of peptide bonds.
  • HMWK's may be extracted from hair using at least two reductive extractions, as described in Crewther, W. G., Fraser, R. D. B., Lennox, F. G., and Lindley, H., “The Chemistry of Keratins” in Advances in Protein Chemistry, Anfinsen, C. B., Jr., Anson, M. L., Edsall, J. T., and Richards, F. M. (Editors), Academic Press, New York, pp. 191-346 (1965), incorporated herein by reference.
  • the hair is oxidized by a suitable oxidizing agent.
  • suitable oxidizing agents include, but are not necessarily limited to hydrogen peroxide, peracetic acid, percarbonates, persulfates, chlorine dioxide, sodium and calcium peroxides, perborates, and hypochlorite.
  • a most preferred oxidizing agent is hydrogen peroxide.
  • the oxidants are used at a concentration of up to about 35%, preferably at from about 0.1% to about 10%. The oxidation preferably occurs at reflux temperatures.
  • the hair is treated with hydrogen peroxide (H.sub.2O.sub.2), at from about 0.1% to about 10%, most preferably 1%, in order to disrupt the cuticle and swell the keratin source material.
  • H.sub.2O.sub.2 hydrogen peroxide
  • This process also converts some fraction of the cystine residues into sulfonic acid groups.
  • the amount of oxidation may be controlled by varying the time of oxidation, preferably from about 0 hours to about 4 hours, while retaining the other conditions of the oxidation reaction constant. These conditions include concentration and type of oxidant, temperature, and ratio of extracting media to keratin source material.
  • the conversion rate of cystine to sulfonic acid residues is roughly proportional to the amount of time used for the oxidation.
  • Residual cystines in the resulting oxidized keratin solids are converted to other sulfur-containing moieties using reductive techniques.
  • the disulfide-bridged cystine group is converted to a thiol group, which has utility of it's own, or can be modified using a variety of chemical techniques.
  • the oxidized hair preferably is treated with a reducing agent.
  • Suitable reducing agents include, but are not necessarily limited to thioglycolic acid and salts thereof, mercaptoethanol, dithiothreitol, thioglycerol, thiolactic acid, glutathione, cysteine, sodium sulfide, and sodium hydrosulfide.
  • Preferred reducing agents are thioglycolic acid and mercaptoethanol, most preferably thioglycolic acid.
  • the previously oxidized hair is suspended in the reducing agent, typically at a concentration of up to about 10N, preferably from about 0.1N and 1N; at a pH greater than about 7, preferably equal to or greater than 9, most preferably 9; a temperature of from about 25 to about 80.degree. C., preferably about 60.degree. C., preferably for a time period of from about 1 to about 72, most preferably about 24 hours.
  • the reaction occurs under an inert atmosphere, preferably nitrogen.
  • the liquid fraction is separated from any remaining solids using known means, including but not necessarily limited to filtration, or cannulation and/or centrifugation, preferably under inert atmosphere. A preferred method of separation is filtration.
  • the soluble keratin proteins are isolated from the solution by addition of a water-miscible non-solvent, or by spray drying.
  • Water-miscible non-solvents include, but are not necessarily limited to ethanol, methanol, isopropyl alcohol, tetrahydrofuran, acetone, dioxane, and the like, again under inert atmosphere.
  • a preferred non-solvent is ethanol.
  • the precipitate is separated from the non-solvent using known means, preferably by filtration and rinsing using additional aliquots of the non-solvent.
  • the resulting keratin proteins are dried using known techniques, preferably overnight under vacuum at room temperature. This process results in the keratins having both sulfonic acid groups and thiol groups.
  • clean, dry human hair is treated with hydrogen peroxide with heating, preferably at reflux, for a period of time effective to achieve scission of disulfide bonds, typically about 180 minutes.
  • the hair is separated from the liquid, preferably by filtration, and the liquid is discarded.
  • the hair was rinsed with water, preferably in copious amounts, and allowed to air dry.
  • the dried, oxidized hair is then treated with a reducing agent, preferably 1M thioglycolic acid at pH 9 (adjusted with ammonium hydroxide), and the mixture is heated, preferably to about 60.degree. C., under inert gas, preferably under a nitrogen atmosphere, for a period of time, preferably 24 hours.
  • the solids are separated from the liquid, preferably by centrifugation.
  • the filtered liquid is added, preferably dropwise, to an excess of ethanol, preferably about an 8-fold volume excess of ethanol, thereby forming a keratin precipitate.
  • the precipitated keratins are isolated by filtration and dried under vacuum. The keratin is ground into a fine powder using a mortar and pestle.
  • a first reductive extraction is performed by treating the hair with a first reducing agent under first conditions effective to selectively extract matrix keratins, producing a first solution comprising soluble reduced matrix keratins (LMWK's) and remaining hair solids (HMWK's).
  • LMWK's soluble reduced matrix keratins
  • HMWK's remaining hair solids
  • the remaining hair solids and the first solution are separated, and the remaining hair solids are exposed to a second extraction solution under second conditions effective to solubilize a-keratins, producing a second solution comprising soluble reduced a-keratins (HMWK's) and solid cuticle.
  • HMWK's soluble reduced a-keratins
  • Suitable reducing agents again include, but are not necessarily limited to thioglycolic acid and salts thereof, mercaptoethanol, dithiothreitol, thioglycerol, thiolactic acid, glutathione, cysteine, sodium sulfide, and sodium hydrosulfide.
  • Preferred reducing agents are thioglycolic acid and mercaptoethanol, most preferably thioglycolic acid.
  • the hair (or other protein source) is suspended in a reducing agent at a concentration of from about 0.1M to about 10M, preferably about 1.0M.
  • gentle swelling of hair fibers is achieved at a pH of about 9 or more, preferably at a pH of from about 9 to about 10.5.
  • the initial reduction takes place at a temperature of from about 20 to about 100.degree. C., preferably at about 25.degree. C.
  • the time period required to accomplish the first reduction is from about 8 to about 36 hours, most preferably about 24 hours.
  • the reaction occurs under an inert atmosphere, preferably nitrogen.
  • the liquid fraction is separated from remaining solids using known means, including but not necessarily limited to filtration, cannulation, and/or centrifugation, preferably under inert atmosphere. A preferred method of separation is filtration.
  • a second extraction is performed using a suitable swelling agent, preferably urea, and/or a base such as ammonium hydroxide, sodium hydroxide, or potassium hydroxide.
  • a most preferred swelling agent for this second extraction is concentrated urea.
  • the second extraction effectively removes the fibrous a-keratins from inside the cuticle.
  • the second extraction occurs at from about 1M to about 10 M urea, preferably about 7M urea, for a period of at least about 1 hour, preferably from about 1 to about 72 hours, more preferably 20 hours or more, most preferably about 24 hours.
  • the second extraction occurs at room temperature, but may take place at temperatures of from about 20.degree. C. to about 100. degree. C., preferably about 25.degree. C.
  • the liquid fraction is separated from the empty, intact cuticle, using known means. Suitable means include but are not necessarily limited to filtration, cannulation and/or centrifugation, preferably under inert atmosphere. A preferred method of separation is filtration.
  • water soluble keratin proteins may be retained in solution for further use, or they may be isolated from the solution by addition to a water-miscible non-solvent, or by spray drying.
  • Water-miscible non-solvents include, but are not necessarily limited to ethanol, methanol, isopropyl alcohol, tetrahydrofuran, acetone, dioxane, and the like, again under inert atmosphere.
  • a preferred non-solvent is ethanol.
  • the precipitate is separated from the non-solvent using known means, preferably by filtration and rinsing using additional aliquots of the non-solvent.
  • the precipitated proteins are dried using known techniques, preferably overnight under vacuum at room temperature.
  • the extracted water soluble keratin proteins (herein sometimes collectively referred to as “water soluble proteins”) comprise thiols or thiol groups.
  • anhydrous solvent include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran.
  • a preferred anhydrous solvent is dichloromethane.
  • the water preferably is deionized water, followed by drying, preferably in air.
  • the implant After cleaning, the implant is immersed in a solution of the coupling material, preferably an organosilane.
  • the coupling material preferably an organosilane.
  • silane compounds in surface coatings is a well-known industrial process. Arkels B. “Tailoring surfaces with silanes.” Chemtech 1977; 7:766-778, incorporated herein by reference.
  • organosilanes passivate and change the chemistry of a surface, they can be used as coupling agents to facilitate the bonding of yet another compound to the outside surface of a substrate.
  • the organosilanes preferably comprise an organic component comprising a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups.
  • Preferred organic components comprise a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, and amine groups. More preferred organic components are selected from the group consisting of epoxy groups, methacrylate groups, alkoxy groups, vinyl groups, and alkylamine groups. Most preferred organic moieties are selected from the group consisting of vinyl groups and epoxy groups.
  • the organosilane preferably comprises substituents selected from the group consisting of from about 1 to 3 halogens and from about 1 to 3 alkoxy groups.
  • a preferred halogen is chlorine.
  • a preferred organosilane, particularly where the surface is titanium, is vinylmethyldichlorosilane (Gelest Inc., Tullytown, Pa.).
  • the organosilane is in an organic solvent.
  • the organic solvent may be substantially any organic solvent that is effective to maintain the organosilane in solution without negatively impacting the bonding process.
  • the organic solvent preferably comprises elements other than oxygen and/or nitrogen.
  • suitable organic solvents include, but are not necessarily limited to alkanes, alkylene chlorides, chloroform, xylenes, and combinations thereof.
  • a preferred alkane is hexane and a preferred alkylene chloride is methylene chloride.
  • a most preferred organic solvent is hexane.
  • the percentage of the organosilane in the organic solvent may vary from about 1 to about 10 weight percent, preferably about 1 weight percent.
  • the substrate is maintained in the solution for a time sufficient to form the coating, suitably from about 1 to about 30 minutes, typically about 10 minutes.
  • the substrate then is removed from solution, rinsed with copious amounts of fresh organic solvent, and allowed to air dry.
  • keratin powder obtained as described above is dissolved in an appropriate solvent.
  • an appropriate solvent is water.
  • an appropriate solvent comprises an aqueous solution comprising a base.
  • bases include, but are not necessarily limited to ammonium hydroxide, sodium hydroxide, and/or potassium hydroxide.
  • a preferred base is ammonium hydroxide.
  • about 15 grams of the keratin powder is dissolved in about 30 mL of 3N ammonium hydroxide.
  • An anhydrous solvent is added.
  • Suitable anhydrous solvents include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran.
  • a preferred anhydrous solvent is dimethylsulfoxide.
  • a suitable catalyst or initiator preferably is used.
  • a suitable initiator or catalyst is used to generate free radicals.
  • An example of such an initiator is a UV activated photoinitiator, such as anthraquinone-2-sulfonic acid or anthraquinone-2-sulfonic acid sodium salt monohydrate (Aldrich; Milwaukee, Wis.). At the foregoing weights and volumes, about 1.5 grams of anthraquinone-2-sulfonic acid sodium salt monohydrate is added. The resulting solution is poured over the silane-coated implant such that it is completely submerged.
  • the coating on the submerged substrate then is cured using an effective energy source, such as a heat lamp, an autoclave, a microwave, or a UV lamp.
  • an effective energy source such as a heat lamp, an autoclave, a microwave, or a UV lamp.
  • the substrate is removed from the solution, rinsed, preferably with copious amounts of deionized water, and allowed to dry, preferably by air.
  • the filtered liquid was added dropwise to an 8-fold volume excess of ethanol, thereby forming a keratin precipitate.
  • the precipitated keratins were isolated by filtration and dried under vacuum.
  • the keratin was ground into a fine powder using a mortar and pestle.
  • Grit blasted titanium test disks with highly controlled and thoroughly characterized surfaces to be used for cellular response were prepared.
  • the material chosen was a medical grade, commercially pure titanium (C.P. Ti).
  • the materials were purchased as large sheets (approximately 5 ft.times.4 ft.times.0.050 in., to ensure metallurgical homogeneity for all sample sets) from Timet (O'Fallon, Mo., USA).
  • 1 ft..times. 1 ft. sheets were cut from the original large single sheet. In order to ensure a consistent surface finish for each disk, surface preparation was performed on these sheets. Each 1 ft..times. 1 ft. sheet was subjected to the aluminum oxide grit blasting process with compressed air using a #20 grit aluminum oxide (Al203) powder for the rough surface finish; grit blasting was performed by Southwest Research Institute (San Antonio, Tex., USA).
  • Quality control of the surface finishing operations was performed and gauged by the consistency of surface roughness measurements.
  • the surface roughness was measured using a diamond stylus contact profilometer at 10 different locations on each 1 ft..times. 1 ft. plate. The roughness measurements were taken in all directions.
  • the average Ra was 9.56 .mu.m with a standard deviation of 1.63 gm.
  • Disks with 14.75 mm diameter and 0.80 mm thickness were prepared for the cell assays.
  • the disks were washed 3 times in a detergent solution and rinsed 2 times with DI water in between each wash. After the final rinse, ethanol was poured over the disks to remove excess water. The disks were air-dried.
  • titanium disks were cleaned by sequential sonication in dichloromethane and deionized water followed by drying in air. Disks were immersed in a 1 weight percent solution of vinylmethyldichlorosilane (Gelest Inc., Tullytown, Pa.) in hexanes for 10 minutes. Each disk was individually removed from solution, rinsed with copious amounts of fresh hexanes, and allowed to air dry.
  • vinylmethyldichlorosilane Gelst Inc., Tullytown, Pa.
  • XPS data was obtained using a Physical Electronics PHI5700 ESCA system with an A1 monochromatic source (A1 Ka radiation at 1486.6 eV).
  • the base pressure in the XPS ultrahigh vacuum chamber was 2 ⁇ 10 ⁇ 10 ton during the analysis.
  • High resolution scans were obtained with a step size of 0.1 eV and pass energy of 11.75 eV.
  • the presence of the silane and keratin coatings was monitored by tracking the atomic concentration of elements that are only present in each of these coatings. Silicon was used for the silane coating and nitrogen for the keratin. Although sulfur is also present in keratin and detected by XPS, it was not used in this work as the signal-to-noise ratio for sulfur was close to 1.5; therefore, the atomic concentrations calculated for the sulfur signal were in the same order as the error bars.
  • N N 0 exp[ ⁇ t /( ⁇ sin ⁇ )]
  • N is the XPS signal (area under the peak) of the substrate with a film on it
  • N 0 is the XPS signal of the clean substrate
  • t is the thickness of the film
  • is the mean-free path of photoelectrons in the film (assumed to be 20 ⁇ in this work)
  • is the angle between the XPS detector and the surface, equal to 45 degrees in this case.
  • Alpha-minimal essential medium (.alpha.-MEM) was purchased from Gibco BRL (Grand Island, N.Y., USA) and fetal bovine serum (FBS) was from Summit Biotechnology (Fort Collins, Colo., USA).
  • FBS fetal bovine serum
  • Formalin was obtained from Electron Microscopy Sciences (Fort Washington, Pa., USA). All other reagents were purchased from Sigma Chemical Co. (St. Louis, Mo., USA).
  • the 2T3 cell line has been isolated and cloned from a transgenic mouse.
  • 2T3 cells undergo bone matrix formation in vitro.
  • 2T3 cells were plated onto each titanium disk in a 12-well plate, one plate per group.
  • the cells were cultured with .alpha.-MEM supplemented with 10% FBS until they reached 90% confluence, approximately day 5.
  • the medium was changed every other day. Once the cells reached confluence, the medium was changed to .alpha.-MEM containing 5% FBS, 100 .mu.g/ml ascorbic acid (AsA) and 5 mM (.beta.-glycerophosphate (.beta.-GP) for the treatment group or to 5% FBS ⁇ .-MEM without AsA and ⁇ GP for the control group.
  • the medium was changed every three days and fresh reagents were added up to day 14, which was the end of the treatment period. Cells were cultured at 37° C., 5% CO 2 .
  • the cells were first washed with PBS and fixed in 10% phosphate buffered formalin for 10 min. The formalin solution was aspirated and the cells were rinsed with deionized water (dH 2 O). Fresh 2% silver nitrate (AgNO 3 ) was added to the cells and the titanium disks with cells were then put under sunlight for 10 minutes. After 10 minutes, the AgNO 3 was removed and the 2T3 cells were rinsed under a steady stream of dH 2 O. A 5% sodium thiosulfate (Na 2 S 2 O 3 ) solution was added to the cells for 3 minutes. The Na 2 S 2 O 3 was removed and the cells were rinsed again with dH 2 O. The following ethanol (EtOH) series was applied to the cells: 95% EtOH for 30 sec., repeat once more followed by two 100% EtOH applications for 30 seconds each. The cells were then allowed to air dry.
  • EtOH ethanol
  • the titanium disks with cells were gold/palladium (Au/Pd) coated for 10 seconds in a sputter coater. Images of the titanium surface were obtained on an Amray scanning electron microscope (SEM) (Amray, Bedford, Mass., USA) at 15 kV. Images were acquired at three magnifications: 100 ⁇ , 500 ⁇ , and 1,000 ⁇ .
  • SEM Amray scanning electron microscope
  • a vinyl-functional silane coupling agent was used to graft keratins onto coated glass and titanium substrates using free radical addition chemistry.
  • a UV activated photoinitiator anthraquinone-2-sulfonic acid, was used to generate free radicals, although thermal initiation with another catalyst could also be used.
  • excellent coating of the substrates was achieved by dipping into a hexane solution of the silane. As shown in FIG. 1 , the resulting increase in water contact angle for titanium disks averaged 38 degrees.
  • the treatment groups included various combinations of keratin coatings with and without the silane coupling, both in the presence and absence of the photoinitiator (designated as “cat.” in FIG. 1 ).
  • the successful coatings were achieved by dipping the titanium disks into a hexanes solution of the silane.
  • the XPS Si2p signals from the untreated titanium disk and a silane-coated titanium disk are shown in FIG. 3 a .
  • the Si signal from the coated disk corresponded to an atomic concentration of 20%, which compared to ⁇ 3% for the untreated disk clearly indicates the presence of the silane coating.
  • the small amount of Si on the untreated disks was likely due to surface contamination.
  • the addition of keratin resulted in an increase of nitrogen atomic concentration from .about 0.3% (background level on an untreated disk) to 8.5%.
  • FIG. 3 b shows the typical N1s XPS signal from an untreated titanium disk and that of the sample coated with silane, the catalyst and keratin.
  • the atomic concentrations of Si and N measured on the different treatment groups are shown in FIG. 4 .
  • the concentration of these two elements correlated very nicely with the presence of the organosilane and the keratin.
  • the addition of the catalyst and keratin on the silane coating resulted in a decrease in the atomic concentration of Si, which results from the attenuation of the silicon signal by the different additional coatings.
  • the titanium XPS signal was used in the attenuation equation described above to calculate the overall film thickness. The results are shown in FIG. 5 .
  • the variations in the thickness of the films with silanes+“cat” or keratin are probably due to variations in the thickness of the silane film itself. Nevertheless, it is clear from the cat+keratin film and the keratin-only film that the keratin film is more robust in the presence of the silane coating.
  • the attenuation equation was used, treating the silane as the substrate and using the silicon signal from silane-coated disks to estimate the thickness of the keratin coatings on top of the silane film.
  • the Si2p XPS signal from the disk coated only with silane was used as the clean substrate signal in this case.
  • the results for several different samples are indicated in parentheses in FIG. 5 .
  • the data indicates that the average thickness of the keratin coatings is .about.8.5 .ANG.
  • the two step dipping process for applying a keratin coating onto titanium substrates resulted in films that were hydrophilic and robust as evidenced by the water contact angle and XPS data, respectively.
  • This process should result in a more biostable coating as the keratin is covalently bonded to the surface.
  • the coating process resulted in very thin layers of both silane and keratin and would not be expected to interfere with the surface topology often employed by implant manufacturers to promote cell attachment to roughened titanium implant surfaces.
  • the 2T3 osteoblast assay showed that the coating promoted attachment, growth, and differentiation. The ability of these cells to produce bony matrix is demonstrative of the keratin coatings osteoconductive properties. In future studies we intend to demonstrate that these keratin coatings are capable of accelerating the rate of bone on growth.

Abstract

A medical device (and method for making same) comprising a passivating coating comprising keratin.

Description

  • The present application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/399,039, filed Jul. 25, 2002, and is a divisional of U.S. Ser. No. 10/626,907, filed Jul. 25, 2003, the disclosures of which are incorporated herein in their entirety by reference.
  • FIELD OF THE INVENTION
  • The present application relates to coatings for medical devices, preferably coatings for medical implants. More particularly, the application relates to bioactive coatings, preferably bioactive coatings comprising keratin having osteoinductive properties.
  • BACKGROUND OF THE INVENTION
  • Many different types of coatings have been developed for purposes of passivating the surface of a medical device. Collagen, hydroxyapatite, and more recently the so-called RGD peptides all have been investigated as coatings in orthopedic implant applications. These materials all have been shown to be at least osteoconductive, but none have been shown to be osteoinductive. Passivating coatings are needed which have osteoinductive properties and which can mask the implant from the human immune system.
  • BRIEF SUMMARY
  • The present application provides a medical implant comprising a passivating coating comprising keratin. The passivating coating comprising a bonding region and a bioactive region. The said bonding region comprises at least one organosilane compound comprising a silane component bound to a surface of said substrate. The bioactive region comprises an organic component of said organosilane bound to a reactive pendant group on the keratin.
  • DETAILED SUMMARY
  • The present application provides substrates comprising a passivating coating comprising keratin. In a preferred embodiment, the passivating coating comprises osteoinductive properties. In a more preferred embodiment, the passivating coating comprises both osteoinductive properties and osteoconductive properties.
  • The substrate preferably resides on a medical device, most preferably a medical implant. The medical device preferably is selected from the group consisting of tissue engineering constructs, orthopedic implants, dental implants, and ventricular assist devices.
  • The substrate comprises a biocompatible material. The biocompatible material preferably is selected from the group consisting of silicon, metals, metal alloys, and ceramics. A preferred metal comprises titanium, and may be titanium metal or an alloy thereof. A preferred ceramic comprises hydroxyapatite.
  • The passivating coating comprises keratin and, in a preferred embodiment, one or more bioactive factors selected from the group consisting of bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-.beta.). The keratin is derived from a material selected from the group consisting of hair, fir, feathers, horns, hooves, beaks, or feet. The keratin preferably is derived from hair, more preferably from human hair, which may be referred to as “human hair keratin.” The keratin also preferably comprises reduced keratin.
  • The passivating coating preferably comprises a bonding region and a bioactive region. The bonding region comprises a material adapted to bond with both a surface of the implant and with reactive pendant groups on the keratin. Preferably, the bonding region comprises at least one silane compound, more preferably an organosilane.
  • The organosilane preferably comprises a silane component and an organic component. The bonding region comprises the silane component bonded with a surface of the medical device and the bioactive region comprises the keratin bonded to the organic component of the organosilane. Suitable organic components for the organosilane are adapted to react with reactive pendant groups on the keratin. The organosilanes preferably comprise an organic component comprising a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups. Preferred organic components comprise a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, and amine groups. More preferred organic components are selected from the group consisting of epoxy groups, acrylate groups, alkoxy groups, vinyl groups, and alkylamine groups. Most preferred organic moieties are selected from the group consisting of vinyl groups and epoxy groups. The organosilane preferably comprises substituents selected from the group consisting of from about 1 to 3 halogens and from about 1 to 3 alkoxy groups. A preferred halogen is chlorine.
  • Also provided is a method of coating a substrate with a passivating substrate. The method comprises: bonding a coupling material to said substrate, producing a bonding region; and, bonding keratin to said bonding region. The method further preferably comprises oxidizing a surface of said substrate before bonding a coupling material to the substrate.
  • In a preferred embodiment the substrate is cleaned before bonding the coupling material to the substrate. Most preferably, the cleaning comprises sonication in anhydrous solvent and sonication in water. Suitable anhydrous solvents include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran. A preferred anhydrous solvent is dichloromethane. The water preferably is deionized water.
  • Bonding keratin to said bonding region comprises dissolving keratin in an appropriate solvent and adding an anhydrous solvent to produce a keratin mixture, exposing said bonding region to said keratin mixture; and curing under conditions effective to produce said bioactive region.
  • For reduced/reduced keratins, an appropriate solvent is water. For oxidized/reduced keratins, an appropriate solvent comprises an aqueous solution comprising a base. Suitable bases include, but are not necessarily limited to ammonium hydroxide, sodium hydroxide, and/or potassium hydroxide. A preferred base is ammonium hydroxide.
  • Suitable anhydrous solvents include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran. A preferred anhydrous solvent is dimethylsulfoxide.
  • The method further comprises mixing the keratin mixture with a reagent selected from the group consisting of a catalyst and an initiator. When a vinyl-functional silane coupling agent is used, a suitable initiator or catalyst generates free radicals. A preferred free radical initiator is selected from the group consisting of anthraquinone-2-sulfonic acid or anthraquinone-2-sulfonic acid sodium salt monohydrate (Aldrich; Milwaukee, Wis.).
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a graph showing the water contact angle of keratin-coated titanium disks, which demonstrates that disks subjected to the process of the present application, silane coating followed by grafting of keratins, had the lowest resulting contact angle.
  • FIG. 2 is a graph showing the water contact angle of keratin-coated substrates demonstrating that both titanium and glass were effectively coated using the dipping process.
  • FIG. 3 is a chart comparing XPS spectra between an untreated titanium disk and a) a silane-coated disk (Si2p spectra) and b) a disk treated with silane, catalyst and keratin (N1s spectra).
  • FIG. 4 is a graph showing Si and N XPS atomic concentrations of keratin-coated titanium disks.
  • FIG. 5 is the estimated thickness of coatings on titanium disks, where the numbers in parenthesis indicate the thickness of the films on the silane coating.
  • FIG. 6 is a micrograph showing that 2T3 cells adhere to and differentiate on keratin-coated titanium disks.
  • DETAILED DESCRIPTION
  • As a family with more than 100 homologues, the biocompatibility of keratins is predetermined by their structural variation. No other human protein offers this magnitude of structural and compositional diversity, and therefore, tolerance by the immune system.
  • The present application selectively extracts keratins from human hair fibers and uses the keratins in a dipping process which produces a molecular coating on the surfaces of medical device materials, such as metals and ceramics. The method uses a coupling agent adapted to bond with both a surface of the implant and with reactive pendant groups on the keratin. Preferably, the bonding region comprises at least one silane compound, more preferably an organosilane. The organosilane preferably comprises a silane component and an organic component, wherein the bonding region comprises the silane component bonded with a surface of the medical device and the organic component bonded with reactive moieties on the keratin. In a preferred embodiment, the silane component of the organosilane is covalently bonded with the surface of the medial device and the organic component of the organosilane is covalently bonded with reactive moieties on the keratin.
  • Characterization of these coatings by water contact angle and X-ray photoelectron spectroscopy (XPS) revealed highly altered surface properties. The angstroms-thin keratin coating was robust, and did not interfere with the normal topology of grit blasted titanium disks. These surface properties were shown to be conducive to the attachment, growth, and differentiation of 2T3 mouse osteoblasts on keratin coated titanium disks in culture.
  • The coating method is generally applicable to medical device materials, which typically comprise metal and ceramic surfaces. The coating method has the potential of producing a more biocompatible interface and ultimately, biologically active surfaces that promote host acceptance and/or accelerate tissue on growth.
  • Keratins
  • Human hair is composed of a tough, tubular outer layer made up of flattened cells arranged in a scaly, overlapping profile known as the cuticle. The inner bulk of the hair is known as the cortex and is constructed from elongated cells that are densely packed with fibrous keratins. The fibrous keratins are arranged in bundles, referred to as macrofibrils, that contain microfibrillar coiled-coils of a-helical keratins. The intermediate filaments (IFs) of this structure are bound together with an to amorphous keratin matrix material. The matrix and IFs vary in function and composition. The matrix is the “glue” that holds the IFs together. This glue is high in sulfur content and is made up of low molecular weight keratins (LMWKs), typically less than 10-15 kDa. The IFs are composed of keratins of relatively low sulfur content but high molecular weight (high molecular weight keratins or HMWKs), generally 50-85 kDa.
  • One distinguishing characteristic of keratins is that they are afforded their structural integrity in large part by the presence of disulfide crosslinks which form a three dimensional network of polypeptide chains. This network structure renders keratins insoluble. Keratins can, however, be made soluble by destroying this three-dimensional structure via diSulfide bond scission. Disulfide bond scission can be done oxidatively, reductively, or by a combination of the two.
  • Disulfide bond scission and selective extraction under controlled conditions results in the isolation of LMWKs from HMWKs. This process serves to remove the cortical proteins without disrupting the cuticle. The inner structure of the hair fiber is removed without substantial damage to the cuticle. The HMWKs from this extraction process give rise to two broad protein bands by gel electrophoresis at molecular weight of 66 kDa and 43 kDa. These keratins are useful as structural biomaterials, including coatings for ceramic and metal surfaces.
  • Growth factors, such as bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-.beta.3), are present in the hair follicle, are deliverable by the coatings, and provide the coatings with osteoinductive and osteoconductive properties.
  • Keratin comprises amino acids, which generally have the formula: I
  • Figure US20090148488A1-20090611-C00001
  • Table 1 summarizes the amino acid residues found in human hair, for example, and shows the “R1” groups associated with each residue.
  • TABLE 1
    Ranked average amounts of amino acids in human hair
    Isoelectric Percent
    Amino Acid R1 Group Nature pKa Point (pH) Composition in Hair
    Cysteine H—S—CH2 Nonpolar  8.4 5.02 17.3
    Glutamic Acid
    Figure US20090148488A1-20090611-C00002
    Polar  4.5 3.22 13.9
    Arginine
    Figure US20090148488A1-20090611-C00003
    Polar 12.5 11.15 9.85
    Serine HO—CH2 Polar None 5.68 9
    Threonine
    Figure US20090148488A1-20090611-C00004
    Polar None 5.64 7.75
    Leucine
    Figure US20090148488A1-20090611-C00005
    Hydrophobic None 5.98 7.35
    Proline
    Figure US20090148488A1-20090611-C00006
    Hydrophobic None 6.3 6.95
    Aspartic Acid
    Figure US20090148488A1-20090611-C00007
    Polar  4.5 2.77 5.8
    Valine
    Figure US20090148488A1-20090611-C00008
    HydroPhobic None 5.96 5.7
    Isoleucine
    Figure US20090148488A1-20090611-C00009
    Hydrophobic None 5.94 4.75
    Glycine H— Nonpolar None 5.65 4.15
    Phenylalanine
    Figure US20090148488A1-20090611-C00010
    Hydrophobic None 5.48 3
    Alanine CH3 Hydrophobic None 6 2.8
    Tyrosine
    Figure US20090148488A1-20090611-C00011
    Hydrophobic None 5.66 2.6
    Lysine NH2—(CH2)4 Polar 10.4 9.59 2.5
    Histidine
    Figure US20090148488A1-20090611-C00012
    Aromatic  6.2 7.47 0.9
    Methionine CH3—S—CH2—CH2 Hydrophobic None 5.74 0.85
    Tryptophan
    Figure US20090148488A1-20090611-C00013
    Hydrophobic None 5.89 0.85
  • The most abundant amino acid in human hair is cysteine, which is found in the form of disulfide-bridged cystine groups. As discussed above, this group can be converted to other sulfur containing moieties, most notably thiol. Thiols theoretically can be reacted with reactive ends of the coupling material using a number of chemical techniques, such as those described in S. Patai (Ed.), the Chemistry of the Thiol Group, Parts 1 and 2, John Wiley & Sons, New York, N.Y. (1974), incorporated herein by reference. Other reaction scenarios, such as those directed toward polymer synthesis, also are useful to utilize thiols to form an assortment of desirable crosslinks, including those described in Rempp, P. and Merrill, E. W., Polymer Synthesis, Huethig & Wepf Verlag Basel, Heidelberg, Germany (1986); Young, R. J. and Lovell, P. A., Introduction to Polymers, Chapman & Hall, London (1991); Odian, G., Principles of Polymerization, John Wiley & Sons, New York, N.Y. (1991), incorporated herein by reference.
  • In addition to cysteine, the following amino acids have pendant groups comprising nitrogen or oxygen which may be useful as reactive pendant groups; arginine, serine, glutamic acid, threonine, aspartic acid, lysine, asparagine, glutamine, tyrosine, tryptophan, and histidine. Where the protein is a-keratin, preferred amino acid residues comprising reactive pendant groups for crosslinking are cysteine, arginine, serine, and glutamic acid, most preferably cysteine and arginine. Disulfide bond scission and keratin extraction
  • The keratins may be processed and/or isolated in a number of ways. Preferably, the processing is sufficient to render the resulting proteins water soluble. Suitable processing techniques include known oxidation techniques, reductive techniques, and/or combinations thereof, as long as the processing renders the proteins water soluble without significant hydrolysis of peptide bonds.
  • A number of reductive chemistries are known for disulfide bond scission in keratins: See Wardell, J. L., “Preparation of Thiols” in The Chemistry of the Thiol Group, Patai, S. (Editor), pp. 163-353, John Wiley & Sons, New York, N.Y. (1974), incorporated herein by reference. HMWK's may be extracted from hair using at least two reductive extractions, as described in Crewther, W. G., Fraser, R. D. B., Lennox, F. G., and Lindley, H., “The Chemistry of Keratins” in Advances in Protein Chemistry, Anfinsen, C. B., Jr., Anson, M. L., Edsall, J. T., and Richards, F. M. (Editors), Academic Press, New York, pp. 191-346 (1965), incorporated herein by reference.
  • The following methods are suitable for processing keratins for use in producing the coatings:
  • Oxidation/Reduction
  • In a preferred embodiment, which uses keratins as a source material (e.g. human hair), the hair is oxidized by a suitable oxidizing agent. Suitable oxidizing agents include, but are not necessarily limited to hydrogen peroxide, peracetic acid, percarbonates, persulfates, chlorine dioxide, sodium and calcium peroxides, perborates, and hypochlorite. A most preferred oxidizing agent is hydrogen peroxide. The oxidants are used at a concentration of up to about 35%, preferably at from about 0.1% to about 10%. The oxidation preferably occurs at reflux temperatures.
  • in a preferred embodiment, the hair is treated with hydrogen peroxide (H.sub.2O.sub.2), at from about 0.1% to about 10%, most preferably 1%, in order to disrupt the cuticle and swell the keratin source material. This process also converts some fraction of the cystine residues into sulfonic acid groups. The amount of oxidation may be controlled by varying the time of oxidation, preferably from about 0 hours to about 4 hours, while retaining the other conditions of the oxidation reaction constant. These conditions include concentration and type of oxidant, temperature, and ratio of extracting media to keratin source material. After the reaction is complete, the oxidized hair is filtered and rinsed, preferably with deionized water. The filtrate is discarded and the hair allowed to dry.
  • Where other conditions of oxidation are maintained constant, the conversion rate of cystine to sulfonic acid residues is roughly proportional to the amount of time used for the oxidation. Residual cystines in the resulting oxidized keratin solids are converted to other sulfur-containing moieties using reductive techniques. Preferably, the disulfide-bridged cystine group is converted to a thiol group, which has utility of it's own, or can be modified using a variety of chemical techniques.
  • The oxidized hair preferably is treated with a reducing agent. Suitable reducing agents include, but are not necessarily limited to thioglycolic acid and salts thereof, mercaptoethanol, dithiothreitol, thioglycerol, thiolactic acid, glutathione, cysteine, sodium sulfide, and sodium hydrosulfide. Preferred reducing agents are thioglycolic acid and mercaptoethanol, most preferably thioglycolic acid.
  • In order to treat the oxidized hair with the reducing agent, the previously oxidized hair is suspended in the reducing agent, typically at a concentration of up to about 10N, preferably from about 0.1N and 1N; at a pH greater than about 7, preferably equal to or greater than 9, most preferably 9; a temperature of from about 25 to about 80.degree. C., preferably about 60.degree. C., preferably for a time period of from about 1 to about 72, most preferably about 24 hours. The reaction occurs under an inert atmosphere, preferably nitrogen. The liquid fraction is separated from any remaining solids using known means, including but not necessarily limited to filtration, or cannulation and/or centrifugation, preferably under inert atmosphere. A preferred method of separation is filtration. Once the solids are removed, the soluble keratin proteins are isolated from the solution by addition of a water-miscible non-solvent, or by spray drying. Water-miscible non-solvents include, but are not necessarily limited to ethanol, methanol, isopropyl alcohol, tetrahydrofuran, acetone, dioxane, and the like, again under inert atmosphere. A preferred non-solvent is ethanol. The precipitate is separated from the non-solvent using known means, preferably by filtration and rinsing using additional aliquots of the non-solvent. The resulting keratin proteins are dried using known techniques, preferably overnight under vacuum at room temperature. This process results in the keratins having both sulfonic acid groups and thiol groups.
  • In a most preferred reaction, clean, dry human hair is treated with hydrogen peroxide with heating, preferably at reflux, for a period of time effective to achieve scission of disulfide bonds, typically about 180 minutes. The hair is separated from the liquid, preferably by filtration, and the liquid is discarded. The hair was rinsed with water, preferably in copious amounts, and allowed to air dry. The dried, oxidized hair is then treated with a reducing agent, preferably 1M thioglycolic acid at pH 9 (adjusted with ammonium hydroxide), and the mixture is heated, preferably to about 60.degree. C., under inert gas, preferably under a nitrogen atmosphere, for a period of time, preferably 24 hours. After reductive extraction, the solids are separated from the liquid, preferably by centrifugation. The filtered liquid is added, preferably dropwise, to an excess of ethanol, preferably about an 8-fold volume excess of ethanol, thereby forming a keratin precipitate. The precipitated keratins are isolated by filtration and dried under vacuum. The keratin is ground into a fine powder using a mortar and pestle.
  • Reductive/Reductive Extraction
  • In another embodiment, a first reductive extraction is performed by treating the hair with a first reducing agent under first conditions effective to selectively extract matrix keratins, producing a first solution comprising soluble reduced matrix keratins (LMWK's) and remaining hair solids (HMWK's). Although it may be possible to subject the LMWK's to the techniques described herein to produce coatings, preferred proteins for use in the techniques herein are HMWK's, which preferably are isolated during a second extraction. The remaining hair solids and the first solution are separated, and the remaining hair solids are exposed to a second extraction solution under second conditions effective to solubilize a-keratins, producing a second solution comprising soluble reduced a-keratins (HMWK's) and solid cuticle.
  • Suitable reducing agents again include, but are not necessarily limited to thioglycolic acid and salts thereof, mercaptoethanol, dithiothreitol, thioglycerol, thiolactic acid, glutathione, cysteine, sodium sulfide, and sodium hydrosulfide. Preferred reducing agents are thioglycolic acid and mercaptoethanol, most preferably thioglycolic acid.
  • In order to selectively reduce and extract the desired proteins, the hair (or other protein source) is suspended in a reducing agent at a concentration of from about 0.1M to about 10M, preferably about 1.0M. Gentle swelling of hair fibers is achieved at a pH of about 9 or more, preferably at a pH of from about 9 to about 10.5. Hence, the initial reduction takes place at a temperature of from about 20 to about 100.degree. C., preferably at about 25.degree. C. The time period required to accomplish the first reduction is from about 8 to about 36 hours, most preferably about 24 hours. The reaction occurs under an inert atmosphere, preferably nitrogen. The liquid fraction is separated from remaining solids using known means, including but not necessarily limited to filtration, cannulation, and/or centrifugation, preferably under inert atmosphere. A preferred method of separation is filtration.
  • A second extraction is performed using a suitable swelling agent, preferably urea, and/or a base such as ammonium hydroxide, sodium hydroxide, or potassium hydroxide. A most preferred swelling agent for this second extraction is concentrated urea. The second extraction effectively removes the fibrous a-keratins from inside the cuticle. The second extraction occurs at from about 1M to about 10 M urea, preferably about 7M urea, for a period of at least about 1 hour, preferably from about 1 to about 72 hours, more preferably 20 hours or more, most preferably about 24 hours. The second extraction occurs at room temperature, but may take place at temperatures of from about 20.degree. C. to about 100. degree. C., preferably about 25.degree. C. The liquid fraction is separated from the empty, intact cuticle, using known means. Suitable means include but are not necessarily limited to filtration, cannulation and/or centrifugation, preferably under inert atmosphere. A preferred method of separation is filtration.
  • Once the cuticle is removed, the water soluble keratin proteins may be retained in solution for further use, or they may be isolated from the solution by addition to a water-miscible non-solvent, or by spray drying. Water-miscible non-solvents include, but are not necessarily limited to ethanol, methanol, isopropyl alcohol, tetrahydrofuran, acetone, dioxane, and the like, again under inert atmosphere. A preferred non-solvent is ethanol. The precipitate is separated from the non-solvent using known means, preferably by filtration and rinsing using additional aliquots of the non-solvent. The precipitated proteins are dried using known techniques, preferably overnight under vacuum at room temperature. The extracted water soluble keratin proteins (herein sometimes collectively referred to as “water soluble proteins”) comprise thiols or thiol groups.
  • Coating Process
  • Cleaning the Surface
  • Before coating the substrate, the surface is cleaned using any suitable procedure. An example of a suitable procedure is sequential sonication in an anhydrous solvent and water. Suitable anhydrous solvents include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran. A preferred anhydrous solvent is dichloromethane. The water preferably is deionized water, followed by drying, preferably in air.
  • Forming the Bonding Region
  • After cleaning, the implant is immersed in a solution of the coupling material, preferably an organosilane. The use of silane compounds in surface coatings is a well-known industrial process. Arkels B. “Tailoring surfaces with silanes.” Chemtech 1977; 7:766-778, incorporated herein by reference. Not only can organosilanes passivate and change the chemistry of a surface, they can be used as coupling agents to facilitate the bonding of yet another compound to the outside surface of a substrate.
  • There are many different types of commercially available organosilanes with a variety of chemical functionalities. The organosilanes preferably comprise an organic component comprising a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups. Preferred organic components comprise a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, and amine groups. More preferred organic components are selected from the group consisting of epoxy groups, methacrylate groups, alkoxy groups, vinyl groups, and alkylamine groups. Most preferred organic moieties are selected from the group consisting of vinyl groups and epoxy groups.
  • The organosilane preferably comprises substituents selected from the group consisting of from about 1 to 3 halogens and from about 1 to 3 alkoxy groups. A preferred halogen is chlorine.
  • A preferred organosilane, particularly where the surface is titanium, is vinylmethyldichlorosilane (Gelest Inc., Tullytown, Pa.). The organosilane is in an organic solvent. The organic solvent may be substantially any organic solvent that is effective to maintain the organosilane in solution without negatively impacting the bonding process. The organic solvent preferably comprises elements other than oxygen and/or nitrogen. Examples of suitable organic solvents include, but are not necessarily limited to alkanes, alkylene chlorides, chloroform, xylenes, and combinations thereof. A preferred alkane is hexane and a preferred alkylene chloride is methylene chloride. A most preferred organic solvent is hexane. The percentage of the organosilane in the organic solvent may vary from about 1 to about 10 weight percent, preferably about 1 weight percent.
  • The substrate is maintained in the solution for a time sufficient to form the coating, suitably from about 1 to about 30 minutes, typically about 10 minutes. The substrate then is removed from solution, rinsed with copious amounts of fresh organic solvent, and allowed to air dry.
  • Forming the Bioactive Region
  • To form the bioactive region, keratin powder obtained as described above is dissolved in an appropriate solvent. For reduced/reduced keratins, an appropriate solvent is water. For oxidized/reduced keratins, an appropriate solvent comprises an aqueous solution comprising a base. Suitable bases include, but are not necessarily limited to ammonium hydroxide, sodium hydroxide, and/or potassium hydroxide. A preferred base is ammonium hydroxide. In a preferred embodiment, about 15 grams of the keratin powder is dissolved in about 30 mL of 3N ammonium hydroxide.
  • An anhydrous solvent is added. Suitable anhydrous solvents include, but are not necessarily limited to methanol, ethanol, isopropyl alcohol, dimethylsulfoxide, acetone, or tetrahydrofuran. A preferred anhydrous solvent is dimethylsulfoxide. At the foregoing weight and volume of keratin and base, about 270 mL of dimethylsulfoxide is added. The mixture is stirred with mild heating until the keratin is dissolved.
  • A suitable catalyst or initiator preferably is used. For example, wherein a vinyl-functional silane coupling agent is used, a suitable initiator or catalyst is used to generate free radicals. An example of such an initiator is a UV activated photoinitiator, such as anthraquinone-2-sulfonic acid or anthraquinone-2-sulfonic acid sodium salt monohydrate (Aldrich; Milwaukee, Wis.). At the foregoing weights and volumes, about 1.5 grams of anthraquinone-2-sulfonic acid sodium salt monohydrate is added. The resulting solution is poured over the silane-coated implant such that it is completely submerged. The coating on the submerged substrate then is cured using an effective energy source, such as a heat lamp, an autoclave, a microwave, or a UV lamp. A preferred energy source is a UV lamp (λ=365 nm, 1.05 amps). Curing is continued for a sufficient period of time to cure the coating, typically from about 1 to about 24 hours, preferably for about 24 hours. After curing, the substrate is removed from the solution, rinsed, preferably with copious amounts of deionized water, and allowed to dry, preferably by air.
  • Persons of ordinary skill in the art will recognize that the foregoing parameters, such as weights, volumes, and times, may be varied depending upon the surface area of the implant, the particular bonding material used, and other factors.
  • The application will be better understood with reference to the following examples, which are illustrative only, and should not be construed as limiting the claims to a particular embodiment. The following materials and methods were used in the examples described below:
  • Materials and Methods
  • Preparation of Keratins
  • In a typical reaction, 500 g of clean, dry human hair was placed in a 12 L round bottom flask. 8,350 mL of 1 weight/volume percent of hydrogen peroxide was added and the reaction heated to reflux for 180 minutes. The hair was separated from the liquid by filtration and the liquid discarded. The hair was rinsed with copious amounts of water and allowed to air dry. 100 g of the dried, oxidized hair was placed in a 2000 mL round bottom flask. 1000 mL of 1 M thioglycolic acid at pH 9 (adjusted with ammonium hydroxide) was added and the mixture was heated to 60.degree. C. under a nitrogen atmosphere for 24 hours. After reductive extraction, the solids were separated from the liquid by centrifugation. The filtered liquid was added dropwise to an 8-fold volume excess of ethanol, thereby forming a keratin precipitate. The precipitated keratins were isolated by filtration and dried under vacuum. The keratin was ground into a fine powder using a mortar and pestle.
  • Titanium Disks
  • Grit blasted titanium test disks with highly controlled and thoroughly characterized surfaces to be used for cellular response were prepared. The material chosen was a medical grade, commercially pure titanium (C.P. Ti). The materials were purchased as large sheets (approximately 5 ft.times.4 ft.times.0.050 in., to ensure metallurgical homogeneity for all sample sets) from Timet (O'Fallon, Mo., USA).
  • 1 ft..times. 1 ft. sheets were cut from the original large single sheet. In order to ensure a consistent surface finish for each disk, surface preparation was performed on these sheets. Each 1 ft..times. 1 ft. sheet was subjected to the aluminum oxide grit blasting process with compressed air using a #20 grit aluminum oxide (Al203) powder for the rough surface finish; grit blasting was performed by Southwest Research Institute (San Antonio, Tex., USA).
  • Quality control of the surface finishing operations was performed and gauged by the consistency of surface roughness measurements. The surface roughness was measured using a diamond stylus contact profilometer at 10 different locations on each 1 ft..times. 1 ft. plate. The roughness measurements were taken in all directions. The average Ra was 9.56 .mu.m with a standard deviation of 1.63 gm.
  • Disks with 14.75 mm diameter and 0.80 mm thickness were prepared for the cell assays. The disks were washed 3 times in a detergent solution and rinsed 2 times with DI water in between each wash. After the final rinse, ethanol was poured over the disks to remove excess water. The disks were air-dried.
  • Coating of Titanium Disks
  • In a typical procedure, titanium disks were cleaned by sequential sonication in dichloromethane and deionized water followed by drying in air. Disks were immersed in a 1 weight percent solution of vinylmethyldichlorosilane (Gelest Inc., Tullytown, Pa.) in hexanes for 10 minutes. Each disk was individually removed from solution, rinsed with copious amounts of fresh hexanes, and allowed to air dry.
  • In a typical keratin coating step, 15 grams of the keratin powder was dissolved in 30 mL of 3N ammonium hydroxide. 270 mL of dimethylsulfoxide was added and the mixture stirred with mild heating until the keratin dissolved. 1.5 grams of anthraquinone-2-sulfonic acid sodium salt monohydrate (Aldrich; Milwaukee, Wis.) was added and the solution poured over the silane-coated titanium disk samples such that they were completely submerged in a shallow glass dish. The glass dish was placed under a UV lamp (.lambda.32 365 nm, 1.05 amps) for 24 hours. After UV exposure, each disk was removed from solution, rinsed with copious amounts of deionized water, and allowed to air dry.
  • Water Contact Angle
  • Contact angles were measured on an optical comparator by placing a 100-.mu.L drop of ultrapure water on the horizontal substrate. Interfacial energies were allowed to equilibrate for 30 seconds prior to obtaining a measurement.
  • X-Ray Photoelectron Spectroscopy (XPS)
  • XPS data was obtained using a Physical Electronics PHI5700 ESCA system with an A1 monochromatic source (A1 Ka radiation at 1486.6 eV). The base pressure in the XPS ultrahigh vacuum chamber was 2×10−10 ton during the analysis. High resolution scans were obtained with a step size of 0.1 eV and pass energy of 11.75 eV. The presence of the silane and keratin coatings was monitored by tracking the atomic concentration of elements that are only present in each of these coatings. Silicon was used for the silane coating and nitrogen for the keratin. Although sulfur is also present in keratin and detected by XPS, it was not used in this work as the signal-to-noise ratio for sulfur was close to 1.5; therefore, the atomic concentrations calculated for the sulfur signal were in the same order as the error bars.
  • XPS was also used to estimate the film thickness. If the signal of a clean substrate is known, then the XPS signal from the substrate with a film on it can be calculated using the following standard attenuation equation

  • N=N 0exp[−t/(λ sin θ)]
  • where N is the XPS signal (area under the peak) of the substrate with a film on it, N0 is the XPS signal of the clean substrate, t is the thickness of the film, λ is the mean-free path of photoelectrons in the film (assumed to be 20 Å in this work), and θ is the angle between the XPS detector and the surface, equal to 45 degrees in this case. C. S. Fadley, Progress in Surface Science 1984; 16: 275-388, incorporated herein by reference.
  • Osteoblast Cell Culture Assay
  • Alpha-minimal essential medium (.alpha.-MEM) was purchased from Gibco BRL (Grand Island, N.Y., USA) and fetal bovine serum (FBS) was from Summit Biotechnology (Fort Collins, Colo., USA). Formalin was obtained from Electron Microscopy Sciences (Fort Washington, Pa., USA). All other reagents were purchased from Sigma Chemical Co. (St. Louis, Mo., USA).
  • Driven by the bone morphogenetic protein 2 (BMP-2) promoter, the 2T3 cell line has been isolated and cloned from a transgenic mouse. Ghosh-Choudhury N, Windle J J, Koop B A, Harris M A, Guerrero, D L, Wozney J M, Mundy G R, and Harris S E. “Immortalized murine osteoblasts derived from BMP2-T-antigen expressing transgenic mice.” Endocrinology 1996; 137:331-339, incorporated herein by reference.
  • These cells undergo bone matrix formation in vitro. 2T3 cells were plated onto each titanium disk in a 12-well plate, one plate per group. The cells were cultured with .alpha.-MEM supplemented with 10% FBS until they reached 90% confluence, approximately day 5. The medium was changed every other day. Once the cells reached confluence, the medium was changed to .alpha.-MEM containing 5% FBS, 100 .mu.g/ml ascorbic acid (AsA) and 5 mM (.beta.-glycerophosphate (.beta.-GP) for the treatment group or to 5% FBS α.-MEM without AsA and βGP for the control group. The medium was changed every three days and fresh reagents were added up to day 14, which was the end of the treatment period. Cells were cultured at 37° C., 5% CO2.
  • Von Kossa Staining
  • The von Kossa cell staining was modified from a previously published procedure. Beresford J N, Graves S E, and Smoothy C A. “Formation of mineralized nodules by bone derived cells in vitro: a model of bone formation?.” Am. J. Med. Genet. 1993; 45:163-78.
  • To fix the 2T3 cells onto the titanium disks, the cells were first washed with PBS and fixed in 10% phosphate buffered formalin for 10 min. The formalin solution was aspirated and the cells were rinsed with deionized water (dH2O). Fresh 2% silver nitrate (AgNO3) was added to the cells and the titanium disks with cells were then put under sunlight for 10 minutes. After 10 minutes, the AgNO3 was removed and the 2T3 cells were rinsed under a steady stream of dH2O. A 5% sodium thiosulfate (Na2S2O3) solution was added to the cells for 3 minutes. The Na2S2O3 was removed and the cells were rinsed again with dH2O. The following ethanol (EtOH) series was applied to the cells: 95% EtOH for 30 sec., repeat once more followed by two 100% EtOH applications for 30 seconds each. The cells were then allowed to air dry.
  • Scanning Electron Microscopy
  • To obtain images of the surface morphology, the titanium disks with cells were gold/palladium (Au/Pd) coated for 10 seconds in a sputter coater. Images of the titanium surface were obtained on an Amray scanning electron microscope (SEM) (Amray, Bedford, Mass., USA) at 15 kV. Images were acquired at three magnifications: 100×, 500×, and 1,000×.
  • Statistical Methods
  • Where indicated, differences between sample groups were determined using a two-tailed Student's t-Test with unequal variance. Statistical significance was established at p values of less than 0.05.
  • EXAMPLE 1
  • In the present study, a vinyl-functional silane coupling agent was used to graft keratins onto coated glass and titanium substrates using free radical addition chemistry. A UV activated photoinitiator, anthraquinone-2-sulfonic acid, was used to generate free radicals, although thermal initiation with another catalyst could also be used. In the first step of this process, excellent coating of the substrates was achieved by dipping into a hexane solution of the silane. As shown in FIG. 1, the resulting increase in water contact angle for titanium disks averaged 38 degrees. The treatment groups included various combinations of keratin coatings with and without the silane coupling, both in the presence and absence of the photoinitiator (designated as “cat.” in FIG. 1). This was done to ascertain the effectiveness of the two step coating approach. Although all of the sample groups resulted in a contact angle different than that of the control titanium group (statistical significance of p<0.05), the full treatment of silane coating followed by covalent grafting of keratin resulted in the most impressive reduction in contact angle compared to the untreated control. The fully treated titanium disk samples had an average contact angle of 7.6 degrees. The results for glass substrates were similar with a reduction in contact angle between the untreated control and the fully treated sample of 16.5 degrees. The keratin treated glass had an average contact angle of 9.0 degrees. These data are shown in FIG. 2. Once it was determined that both titanium disks and glass microscope slides could be coated, only the titanium disks were used in further evaluations.
  • As mentioned previously, the successful coatings were achieved by dipping the titanium disks into a hexanes solution of the silane. The XPS Si2p signals from the untreated titanium disk and a silane-coated titanium disk are shown in FIG. 3 a. The Si signal from the coated disk corresponded to an atomic concentration of 20%, which compared to <3% for the untreated disk clearly indicates the presence of the silane coating. The small amount of Si on the untreated disks was likely due to surface contamination. The addition of keratin resulted in an increase of nitrogen atomic concentration from .about 0.3% (background level on an untreated disk) to 8.5%. FIG. 3 b shows the typical N1s XPS signal from an untreated titanium disk and that of the sample coated with silane, the catalyst and keratin. The atomic concentrations of Si and N measured on the different treatment groups are shown in FIG. 4. The concentration of these two elements correlated very nicely with the presence of the organosilane and the keratin.
  • The addition of the catalyst and keratin on the silane coating resulted in a decrease in the atomic concentration of Si, which results from the attenuation of the silicon signal by the different additional coatings. The titanium XPS signal was used in the attenuation equation described above to calculate the overall film thickness. The results are shown in FIG. 5. The variations in the thickness of the films with silanes+“cat” or keratin are probably due to variations in the thickness of the silane film itself. Nevertheless, it is clear from the cat+keratin film and the keratin-only film that the keratin film is more robust in the presence of the silane coating.
  • In order to exclude variations in the silane film and to more accurately determine the thickness of the keratin coating, the attenuation equation was used, treating the silane as the substrate and using the silicon signal from silane-coated disks to estimate the thickness of the keratin coatings on top of the silane film. The Si2p XPS signal from the disk coated only with silane was used as the clean substrate signal in this case. The results for several different samples are indicated in parentheses in FIG. 5. The data indicates that the average thickness of the keratin coatings is .about.8.5 .ANG.
  • Differentiation and mineralization of osteoblasts on keratin coated titanium disks were demonstrated by von Kossa analysis of the disk surfaces. Nodule formation is considered to be an important step toward mineralization in vitro.
  • Cells were cultured in a-MEM containing 5% PBS in the presence (+) or absence (−) of 100 .mu.g/ml ascorbic acid and 5 mM .beta.-glycerophosphate. Differentiation and mineralization of osteoblasts as demonstrated by von Kossa analysis (panels A and C) without (−) AsA and β.-GP showed smaller and fewer nodules. After 2 weeks, 2T3 cells were observed to mineralize larger nodules on the implant surface in the presence (+) of 100 μg/ml AsA and 5 mM β-GP panels B and D). Images A and B were acquired at 100× magnification (scale bar=100 μ.m) and C and D at 1,000× magnification (scale bar=10 μ.m).
  • The mineralization of nodules in vitro appears to resemble the in vivo produced woven bone. After 2 weeks, 2T3 cells were observed to mineralize in culture on the implant surface with or without AsA and β-GP. Without AsA and β.-GP, von Kossa staining of the cells at 2 weeks showed smaller and fewer nodules (FIGS. 6A and C). In contrast, there were more and larger nodules on AsA and β-GP treated disks (FIGS. 6B and D). The ability of AsA and β-GP to induce nodule formation in 2T3 osteoblasts on collagen coated substrates has been previously reported. In this study, we find similar results for keratin coated substrates, thus indicating biocompatibility.
  • The two step dipping process for applying a keratin coating onto titanium substrates resulted in films that were hydrophilic and robust as evidenced by the water contact angle and XPS data, respectively. This process should result in a more biostable coating as the keratin is covalently bonded to the surface. The coating process resulted in very thin layers of both silane and keratin and would not be expected to interfere with the surface topology often employed by implant manufacturers to promote cell attachment to roughened titanium implant surfaces. The 2T3 osteoblast assay showed that the coating promoted attachment, growth, and differentiation. The ability of these cells to produce bony matrix is demonstrative of the keratin coatings osteoconductive properties. In future studies we intend to demonstrate that these keratin coatings are capable of accelerating the rate of bone on growth.
  • Persons of ordinary skill in the art will recognize that many modifications may be made to the foregoing without departing from the spirit and scope thereof. The embodiment described herein is meant to be illustrative only and should not be taken as limiting the invention, which is defined in the following claims.

Claims (47)

1.-33. (canceled)
34. A medical implant comprising:
a substrate comprising a passivating coating comprising keratin, said passivating coating being effective to increase bone matrix formation by cultured 2T3 mouse osteoblasts, said passivating coating comprising a bonding region and a bioactive region;
said bonding region comprising at least one organosilane compound comprising a silane component bound to a surface of said substrate; and
said bioactive region comprising an organic component of said organosilane bound to a reactive pendant group on said keratin.
35. The medical implant of claim 34 wherein said silane component of said organosilane compound is covalently bonded with a surface of the substrate.
36. The medical implant of claim 34 wherein said bioactive region comprises reactive pendant groups on said keratin covalently bonded to said organic component of said organosilane.
37. (canceled)
38. The medical implant of claim 34 wherein said passivating coating comprises keratin and one or more bioactive factors selected from bone morphogenetic protein and transforming growth factor beta.
39-41. (canceled)
42. The medical implant of claim 34 wherein said organic component of said organosilane comprises a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups.
43. (canceled)
44. The medical implant of claim 42 wherein said amine groups are alkylamine groups.
45. The medical implant of claim 34 wherein said organic component comprises a moiety selected from the group consisting of vinyl groups and epoxy groups.
46-57. (canceled)
58. The medical implant of claim 34 wherein said organosilane comprises substituents selected from 1 to 3 halogens and 1 to 3 alkoxy groups.
59-70. (canceled)
71. The medical implant of claim 34 wherein said keratin comprises keratin having a molecular weight of from about 50 to about 85 kDa.
72-160. (canceled)
161. A medical implant comprising:
a substrate comprising a passivating coating comprising keratin, said passivating coating comprising a bonding region and a bioactive region;
said bonding region comprising at least one organosilane compound comprising a silane component bound to a surface of said substrate; and
said bioactive region comprising an organic component of said organosilane bound to a reactive pendant group on said keratin.
162. The medical implant of claim 161 wherein said silane component of said organosilane compound is covalently bonded with a surface of the substrate.
163. The medical implant of claim 161 wherein said bioactive region comprises reactive pendant groups on said keratin covalently bonded to said organic component of said organosilane.
164. (canceled)
165. The medical implant of claim 161 wherein said organic component of said organosilane comprises a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups.
166. (canceled)
167. The medical implant of claim 165 wherein said amine groups are alkylamine groups.
168. The medical implant of claim 161 wherein said organic component comprises a moiety selected from the group consisting of vinyl groups and epoxy groups.
169. The medical implant of claim 163 wherein said organic component of said organosilane comprises a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups.
170. The medical implant of claim 163 wherein said organic component of said organosilane comprises a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, and amine groups.
171. The medical implant of claim 170 wherein said amine groups are alkylamine groups.
172.-176. (canceled)
177. The medical implant of claim 161 wherein said organosilane comprises substituents are selected from 1 to 3 halogens and 1 to 3 alkoxy groups.
178-185. (canceled)
186. The medical implant of claim 161 wherein said keratin comprises keratin having a molecular weight of from about 50 to about 85 kDa.
187-199. (canceled)
200. The medical implant of claim 161 wherein the substrate comprises one or more biocompatible material is selected from the group consisting of silicon, metals, metal alloys, and ceramics.
201. The medical implant of claim 161 wherein said biocompatible material is selected from the group consisting of titanium and hydroxyapatite.
202. The medical implant of claim 161 wherein said biocompatible material comprises silicon.
203-220. (canceled)
221. An orthopedic medical implant comprising:
a substrate comprising a passivating coating comprising keratin, said passivating coating comprising a bonding region and a bioactive region;
said bonding region comprising at least one organosilane compound comprising a silane component covalently bound to a surface of said substrate; and
said bioactive region comprising an organic component of said organosilane bound to a reactive pendant group on said keratin.
222. The orthopedic implant of claim 221 wherein said organic component of said organosilane comprises a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, amine groups, isocyanate groups, and carboxyl groups.
223. The orthopedic implant of claim 222 wherein said amine groups are alkylamine groups.
224. The orthopedic implant of claim 221 wherein said organic component comprises a moiety selected from the group consisting of vinyl groups and epoxy groups.
225. The medical implant of claim 221 wherein said organic component of said organosilane comprises a moiety selected from the group consisting of epoxy groups, alkoxy groups, vinyl groups, and amine groups.
226. The medical implant of claim 227 wherein said amine groups are alkylamine groups.
227. The medical implant of claim 221 wherein said organosilane comprises substituents are selected from 1 to 3 halogens and 1 to 3 alkoxy groups.
228. The medical implant of claim 221 wherein said keratin comprises keratin having a molecular weight of from about 50 to about 85 kDa.
229. The medical implant of claim 221 wherein the substrate comprises one or more biocompatible material is selected from the group consisting of silicon, metals, metal alloys, and ceramics.
230. The medical implant of claim 221 wherein said biocompatible material is selected from the group consisting of titanium and hydroxyapatite.
231. The medical implant of claim 221 wherein said biocompatible material comprises silicon.
US12/390,360 2002-07-25 2009-02-20 Bioactive coating for medical devices Abandoned US20090148488A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/390,360 US20090148488A1 (en) 2002-07-25 2009-02-20 Bioactive coating for medical devices

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39903902P 2002-07-25 2002-07-25
US10/626,907 US20050058686A1 (en) 2002-07-25 2003-07-25 Bioactive coating for medical devices
US12/390,360 US20090148488A1 (en) 2002-07-25 2009-02-20 Bioactive coating for medical devices

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/626,907 Division US20050058686A1 (en) 2002-07-25 2003-07-25 Bioactive coating for medical devices

Publications (1)

Publication Number Publication Date
US20090148488A1 true US20090148488A1 (en) 2009-06-11

Family

ID=31188534

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/622,248 Expired - Lifetime US7163321B2 (en) 2002-07-25 2003-07-18 Emergency vehicle grille
US10/626,907 Abandoned US20050058686A1 (en) 2002-07-25 2003-07-25 Bioactive coating for medical devices
US12/390,360 Abandoned US20090148488A1 (en) 2002-07-25 2009-02-20 Bioactive coating for medical devices

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/622,248 Expired - Lifetime US7163321B2 (en) 2002-07-25 2003-07-18 Emergency vehicle grille
US10/626,907 Abandoned US20050058686A1 (en) 2002-07-25 2003-07-25 Bioactive coating for medical devices

Country Status (9)

Country Link
US (3) US7163321B2 (en)
EP (1) EP1551471B1 (en)
JP (2) JP4991032B2 (en)
AT (1) ATE427127T1 (en)
AU (1) AU2003261242B2 (en)
CA (1) CA2493555A1 (en)
DE (1) DE60326973D1 (en)
NZ (1) NZ538218A (en)
WO (1) WO2004011052A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096700A1 (en) * 2021-11-23 2023-06-01 University Of Cincinnati Electrochemical aptamer sensors with non-monolayer blocking layers

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865939B1 (en) * 2004-02-06 2007-08-31 Biomatlante USE OF SILANIZED ORGANIC POLYMERS FOR CREATING BIOACTIVE COATING, FOR IMPLANT OR PROSTHESIS
US7439012B2 (en) 2004-08-17 2008-10-21 Wake Forest University Health Sciences Ambient stored blood plasma expanders containing keratose
JP2009527274A (en) * 2006-02-17 2009-07-30 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ Coatings and biomedical implants formed from keratin biomedical materials
US8273702B2 (en) 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US9392935B2 (en) 2006-11-07 2016-07-19 Hologic, Inc. Methods for performing a medical procedure
PL227142B1 (en) * 2006-11-21 2017-11-30 Inst Medycyny Doświadczalnej I Klinicznej Im M Mossakowskiego Polskiej Akademii Nauk New microstructured protein preparations with adsorbed biologically active substances as well as their medicinal and cosmetic applications
US9068162B2 (en) * 2007-08-17 2015-06-30 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
US20090047260A1 (en) * 2007-08-17 2009-02-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
US20090072556A1 (en) * 2007-09-16 2009-03-19 Conrad Michael Kudelko Non-Opaque Radiator Grilles for Automotive Vehicles
US9045600B2 (en) 2009-05-13 2015-06-02 Keraplast Technologies, Ltd. Biopolymer materials
AU2012296477B2 (en) 2011-08-17 2017-04-27 Keratin Biosciences, Inc. Methods for extracting keratin proteins
CA2845267C (en) 2011-08-17 2021-07-06 Keranetics Llc Low protein percentage gelling compositions
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone
WO2015023380A1 (en) * 2013-08-16 2015-02-19 Exxonmobil Chemical Patents Inc. Polyamide-polyolefin copolymers and methods of making them
US10576877B2 (en) 2017-03-24 2020-03-03 Honda Patents & Technologies North America, Llc Illuminated grille
US11027641B2 (en) * 2017-10-09 2021-06-08 AAC Enterprises LLC Front grill with LED module lighting system
CN107737378A (en) * 2017-10-10 2018-02-27 东华大学 A kind of keratin hydroxyapatite composite membrane improved using silane coupler, preparation method and applications
US10479296B2 (en) 2018-03-02 2019-11-19 Ford Global Technologies, Llc Smart grille assembly and modular grille assembly system for a motor vehicle
CN110787322B (en) * 2019-11-19 2021-11-30 佛山科学技术学院 Mineralized keratin bionic material and preparation method thereof
US11312323B2 (en) 2020-05-12 2022-04-26 Pro-Gard Products Llc Front grille light assembly for emergency vehicles
EP4311726A1 (en) * 2022-07-25 2024-01-31 Coplus Inc. Car radiator cover

Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US922692A (en) * 1907-10-07 1909-05-25 Byron B Goldsmith Thermoplastic keratin composition.
US926999A (en) * 1907-11-25 1909-07-06 Carl Neuberg Process of producing digestible substances from keratin.
US960914A (en) * 1909-09-21 1910-06-07 Arthur Heinemann Pills for the treatment of diabetes mellitus.
US2434688A (en) * 1942-11-03 1948-01-20 Ralph L Evans Regenerated keratin
US3250682A (en) * 1961-02-22 1966-05-10 Wella Ag Method of setting hair with epoxy resin compositions
US3642498A (en) * 1969-09-18 1972-02-15 Gen Mills Inc Method of preparing keratin-containing films and coatings
US3677693A (en) * 1969-11-18 1972-07-18 Iws Nominee Co Ltd Method of milling and resin treating keratinous fibers
US4423032A (en) * 1981-02-05 1983-12-27 Kao Soap Co., Ltd. Hair treatments
US4474694A (en) * 1982-11-08 1984-10-02 Ralston Purina Company Modified protein adhesive binder and method of producing
US4504644A (en) * 1982-08-23 1985-03-12 L'oreal Protein derivative containing grafted ultraviolet-absorbing radicals, the process for its preparation and composition in which it is present
US4570629A (en) * 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
US4751074A (en) * 1980-11-17 1988-06-14 Kao Soap Co., Ltd. Hair rinse composition
US4895722A (en) * 1981-03-03 1990-01-23 Kao Soap Co., Ltd. Hair treatments
US5047249A (en) * 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5073294A (en) * 1990-03-07 1991-12-17 Hercules Incorporated Process of preparing compositions having multiple oriented mesogens
US5202053A (en) * 1991-02-22 1993-04-13 Hercules Incorporated Polymerizable nematic monomer compositions
US5258501A (en) * 1988-11-25 1993-11-02 Slobodan Barbaric Stabilization of glycoproteins
US5276138A (en) * 1990-09-17 1994-01-04 Kurashiki Boseki Kabushiki Kaisha Process for solubilizing animal hair
US5300285A (en) * 1992-10-13 1994-04-05 Dow Corning Corporation Permanent waving with silicones
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5358935A (en) * 1992-11-19 1994-10-25 Robert Allen Smith Nonantigenic keratinous protein material
US5412076A (en) * 1992-06-18 1995-05-02 Flamel Technologies Crosslinkable collagen derivatives, process for their production and their application to the preparation of biomaterials
US5505952A (en) * 1994-04-19 1996-04-09 United States Surgical Corporation Modified synthetic cross-linked amino acid polymers and medical devices formed therefrom
US5520925A (en) * 1992-08-21 1996-05-28 Naturin Gmbh & Co. Material on the basis of collagen fibers for covering wounds
US5563230A (en) * 1994-09-09 1996-10-08 National Science Council Chiral smectic liquid crystalline polymers
US5654471A (en) * 1994-12-01 1997-08-05 Consortium Fur Elektrochemische Industrie Gmbh Process for the preparation of 4-hydroxyphenyl benzoate derivatives
US5679819A (en) * 1995-04-04 1997-10-21 Croda International Plc Cystine-silicone copolymers and their use for treating keratin substrates
US5712252A (en) * 1996-03-08 1998-01-27 The University Of Tennessee Research Corporation Method of augmenting soft tissue in mammals
US5824651A (en) * 1993-05-10 1998-10-20 Universite De Montreal Process for modification of implant surface with bioactive conjugates for improved integration
US5833880A (en) * 1994-03-11 1998-11-10 Basf Aktiengesellschaft Polymerizable liquid-crystalline compounds
US5948432A (en) * 1997-11-26 1999-09-07 Keraplast Technologies Ltd. Keratin-based sheet material for biomedical applications and method of production
US5955549A (en) * 1997-05-29 1999-09-21 Chang; Ching-Jen Crosslinked poly(amino acids) and method of preparation
US5989461A (en) * 1996-07-04 1999-11-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Circular UV polarizer
US6013855A (en) * 1996-08-06 2000-01-11 United States Surgical Grafting of biocompatible hydrophilic polymers onto inorganic and metal surfaces
US6090308A (en) * 1995-02-06 2000-07-18 Merck Patent Gesellschaft Direactive mesogenic compounds and intermediates
US6110487A (en) * 1997-11-26 2000-08-29 Keraplast Technologies Ltd. Method of making porous keratin scaffolds and products of same
US6159496A (en) * 1997-11-26 2000-12-12 Keraplast Technologies, Ltd. Keratin-based hydrogel for biomedical applications and method of production
US6329448B1 (en) * 1997-09-05 2001-12-11 Basf Aktiengesellschaft Method for producing dyed moulding materials
US6344061B1 (en) * 1996-05-10 2002-02-05 Isotis N.V. Device for incorporation and release of biologically active agents
US6352699B1 (en) * 1997-04-04 2002-03-05 L'oreal Cosmetic or dermatological composition forming, on a keratin substrate, a film in cross-linked hybrid material
US6443942B2 (en) * 1996-11-01 2002-09-03 Minimed, Inc. Medication device with protein stabilizing surface coating
US6706408B2 (en) * 2002-05-16 2004-03-16 Surmodics, Inc. Silane coating composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2336413A (en) * 1941-12-06 1943-12-07 Nicholas M Michailovsky Driving light
JPS57178946A (en) * 1981-04-30 1982-11-04 Hashimoto Forming Co Ltd Lighting apparatus fixing method for car radiator grill
JPS59155248A (en) * 1983-02-22 1984-09-04 テルモ株式会社 Coating membrane and production thereof
JPS6294450A (en) * 1985-10-21 1987-04-30 Nissan Motor Co Ltd Fitting struction for front side shield
JPH078273A (en) * 1993-06-14 1995-01-13 Kurabo Ind Ltd Serumfree culture of adhesive animal cell
US5373426A (en) * 1993-09-24 1994-12-13 O'sullivan; Alan L. Front-mounted vehicle brake light
US5617883A (en) * 1994-09-14 1997-04-08 Shiseido Co., Ltd. Reducing agents for permanent waving of hair
SE9604293D0 (en) * 1996-11-22 1996-11-22 Lennart Gaelliner Strålkastararrangemang
US6371984B1 (en) * 1999-09-13 2002-04-16 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6357707B1 (en) * 2000-01-07 2002-03-19 Jimmy W. Lindsay Mounting clamp
US20030004568A1 (en) * 2001-05-04 2003-01-02 Concentric Medical Coated combination vaso-occlusive device
WO2003008006A1 (en) * 2001-07-19 2003-01-30 Dempsey, Donald, J. Bioactive surface for titanium implants
US8187326B2 (en) * 2002-05-22 2012-05-29 Advanced Technologies And Regenerative Medicine, Llc. Attachment of absorbable tissue scaffolds to fixation devices

Patent Citations (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US922692A (en) * 1907-10-07 1909-05-25 Byron B Goldsmith Thermoplastic keratin composition.
US926999A (en) * 1907-11-25 1909-07-06 Carl Neuberg Process of producing digestible substances from keratin.
US960914A (en) * 1909-09-21 1910-06-07 Arthur Heinemann Pills for the treatment of diabetes mellitus.
US2434688A (en) * 1942-11-03 1948-01-20 Ralph L Evans Regenerated keratin
US3250682A (en) * 1961-02-22 1966-05-10 Wella Ag Method of setting hair with epoxy resin compositions
US3642498A (en) * 1969-09-18 1972-02-15 Gen Mills Inc Method of preparing keratin-containing films and coatings
US3677693A (en) * 1969-11-18 1972-07-18 Iws Nominee Co Ltd Method of milling and resin treating keratinous fibers
US4751074A (en) * 1980-11-17 1988-06-14 Kao Soap Co., Ltd. Hair rinse composition
US4423032A (en) * 1981-02-05 1983-12-27 Kao Soap Co., Ltd. Hair treatments
US4895722A (en) * 1981-03-03 1990-01-23 Kao Soap Co., Ltd. Hair treatments
US4570629A (en) * 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
US4504644A (en) * 1982-08-23 1985-03-12 L'oreal Protein derivative containing grafted ultraviolet-absorbing radicals, the process for its preparation and composition in which it is present
US4474694A (en) * 1982-11-08 1984-10-02 Ralston Purina Company Modified protein adhesive binder and method of producing
US5047249A (en) * 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5258501A (en) * 1988-11-25 1993-11-02 Slobodan Barbaric Stabilization of glycoproteins
US5073294A (en) * 1990-03-07 1991-12-17 Hercules Incorporated Process of preparing compositions having multiple oriented mesogens
US5276138A (en) * 1990-09-17 1994-01-04 Kurashiki Boseki Kabushiki Kaisha Process for solubilizing animal hair
US5202053A (en) * 1991-02-22 1993-04-13 Hercules Incorporated Polymerizable nematic monomer compositions
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5412076A (en) * 1992-06-18 1995-05-02 Flamel Technologies Crosslinkable collagen derivatives, process for their production and their application to the preparation of biomaterials
US5520925A (en) * 1992-08-21 1996-05-28 Naturin Gmbh & Co. Material on the basis of collagen fibers for covering wounds
US5300285A (en) * 1992-10-13 1994-04-05 Dow Corning Corporation Permanent waving with silicones
US5358935A (en) * 1992-11-19 1994-10-25 Robert Allen Smith Nonantigenic keratinous protein material
US5824651A (en) * 1993-05-10 1998-10-20 Universite De Montreal Process for modification of implant surface with bioactive conjugates for improved integration
US5833880A (en) * 1994-03-11 1998-11-10 Basf Aktiengesellschaft Polymerizable liquid-crystalline compounds
US5505952A (en) * 1994-04-19 1996-04-09 United States Surgical Corporation Modified synthetic cross-linked amino acid polymers and medical devices formed therefrom
US5563230A (en) * 1994-09-09 1996-10-08 National Science Council Chiral smectic liquid crystalline polymers
US5654471A (en) * 1994-12-01 1997-08-05 Consortium Fur Elektrochemische Industrie Gmbh Process for the preparation of 4-hydroxyphenyl benzoate derivatives
US6090308A (en) * 1995-02-06 2000-07-18 Merck Patent Gesellschaft Direactive mesogenic compounds and intermediates
US5679819A (en) * 1995-04-04 1997-10-21 Croda International Plc Cystine-silicone copolymers and their use for treating keratin substrates
US5712252A (en) * 1996-03-08 1998-01-27 The University Of Tennessee Research Corporation Method of augmenting soft tissue in mammals
US6344061B1 (en) * 1996-05-10 2002-02-05 Isotis N.V. Device for incorporation and release of biologically active agents
US5989461A (en) * 1996-07-04 1999-11-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Circular UV polarizer
US6013855A (en) * 1996-08-06 2000-01-11 United States Surgical Grafting of biocompatible hydrophilic polymers onto inorganic and metal surfaces
US6443942B2 (en) * 1996-11-01 2002-09-03 Minimed, Inc. Medication device with protein stabilizing surface coating
US6352699B1 (en) * 1997-04-04 2002-03-05 L'oreal Cosmetic or dermatological composition forming, on a keratin substrate, a film in cross-linked hybrid material
US5955549A (en) * 1997-05-29 1999-09-21 Chang; Ching-Jen Crosslinked poly(amino acids) and method of preparation
US6329448B1 (en) * 1997-09-05 2001-12-11 Basf Aktiengesellschaft Method for producing dyed moulding materials
US5948432A (en) * 1997-11-26 1999-09-07 Keraplast Technologies Ltd. Keratin-based sheet material for biomedical applications and method of production
US6165496A (en) * 1997-11-26 2000-12-26 Keraplast Technologies, Ltd. Keratin-based sheet material for biomedical applications and method of production
US6159496A (en) * 1997-11-26 2000-12-12 Keraplast Technologies, Ltd. Keratin-based hydrogel for biomedical applications and method of production
US6159495A (en) * 1997-11-26 2000-12-12 Keraplast Technologies, Ltd. Porous and bulk keratin bio-polymers
US6124265A (en) * 1997-11-26 2000-09-26 Keraplast Technologies, Ltd. Method of making and cross-linking keratin-based films and sheets
US6110487A (en) * 1997-11-26 2000-08-29 Keraplast Technologies Ltd. Method of making porous keratin scaffolds and products of same
US6706408B2 (en) * 2002-05-16 2004-03-16 Surmodics, Inc. Silane coating composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096700A1 (en) * 2021-11-23 2023-06-01 University Of Cincinnati Electrochemical aptamer sensors with non-monolayer blocking layers

Also Published As

Publication number Publication date
JP4991032B2 (en) 2012-08-01
DE60326973D1 (en) 2009-05-14
JP2005537831A (en) 2005-12-15
EP1551471B1 (en) 2009-04-01
US20050058686A1 (en) 2005-03-17
NZ538218A (en) 2008-04-30
US7163321B2 (en) 2007-01-16
US20040057242A1 (en) 2004-03-25
ATE427127T1 (en) 2009-04-15
AU2003261242B2 (en) 2009-12-17
WO2004011052A1 (en) 2004-02-05
EP1551471A1 (en) 2005-07-13
CA2493555A1 (en) 2004-02-05
AU2003261242A1 (en) 2004-02-16
JP2012011233A (en) 2012-01-19

Similar Documents

Publication Publication Date Title
US20090148488A1 (en) Bioactive coating for medical devices
EP2919920B1 (en) Method for grafting polymers on metallic substrates
US6616982B2 (en) Poly(ethylene oxide) coated surfaces
JP2855224B2 (en) Preparation of polymer surface
JP2002506688A (en) Potentially reactive blood compatible agents
US20060165618A1 (en) Photoactivatable composition and uses thereof
EP0494216A1 (en) Surfaces having desirable cell adhesive effects.
US11332840B2 (en) Electrochemical attachment of phosphonic acids to metallic substrates and osteoconductive medical devices containing same
Brunette et al. Biochemical modification of titanium surfaces
Oh et al. Effect of RGD peptide-coated TiO2 nanotubes on the attachment, proliferation, and functionality of bone-related cells
WO2018210862A1 (en) Highly hydrophilic coatings for biomedical applications
JP2010088933A (en) Peptide-coated implant and method for preparing the same
KR20180137508A (en) Dental prostheses and parts thereof
EP2236524A1 (en) Adhesion promoter based on a functionalized macromolecule comprising photoreactive groups
EP0472936A2 (en) Process for modifying surfaces
EP2124819B1 (en) Process for the manufacture of a composite material
JP6041132B2 (en) Material surface modification method
Paredes et al. Cell study of the biomimetic modifications on a CoCrMo alloy for biomedical applications
Xiao¹ et al. 13 Biochemical Modification of Titanium Surfaces
Stewart The development of protein-functionalised plasma polymer biointerfaces for orthopaedic applications
Hanawa et al. Biofunctional hybrid of titanium with polymers
Xiao Tailored organic thin films on gold and titanium: Peptide-grafting, protein resistance and physical characterization

Legal Events

Date Code Title Description
AS Assignment

Owner name: KMS VENUTRES, INC.,TEXAS

Free format text: SECURITY AGREEMENT;ASSIGNOR:KERAPLAST TECHNOLOGIES, LLC;REEL/FRAME:024483/0526

Effective date: 20100511

Owner name: KMS VENUTRES, INC., TEXAS

Free format text: SECURITY AGREEMENT;ASSIGNOR:KERAPLAST TECHNOLOGIES, LLC;REEL/FRAME:024483/0526

Effective date: 20100511

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION